MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$3,109K
(-78.02%↓ Y/Y)
Net cash provided by
financing activities
$2,719K
(-79.62%↓ Y/Y)
Canceled cashflow
$390K
Net (decrease) in
cash, cash...
-$3,379K
(70.04%↑ Y/Y)
Canceled cashflow
$2,719K
Payable-in-kind interest on
credit agreement
$3,409K
(-37.25%↓ Y/Y)
Accounts payable,
accrued expenses, due to...
$1,833K
(3973.33%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,678K
(-149.33%↓ Y/Y)
Accretion of debt discount
and amortization of...
$774K
(4.17%↑ Y/Y)
Change in fair value of
derivative liabilities
-$394K
(-105.46%↓ Y/Y)
Stock-based compensation
expense
$358K
(-79.38%↓ Y/Y)
Accounts receivable
-$134K
(-17.54%↓ Y/Y)
Depreciation
$18K
(-88.08%↓ Y/Y)
Inventory
-$17K
(90.17%↑ Y/Y)
Payment of principal of
long-term debt
$304K
Offering costs for common
stock and warrants...
$62K
(-92.31%↓ Y/Y)
Payment of employee tax
obligations related to...
$24K
(2300.00%↑ Y/Y)
Net cash used in
operating activities
-$6,098K
(75.23%↑ Y/Y)
Canceled cashflow
$8,615K
Net loss
-$14,713K
(44.36%↑ Y/Y)
Back
Back
Cash Flow
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)
source: myfinsight.com